文档介绍：Clinical Practice Guidelines
EASL Clinical Practice Guidelines: Management of chronic
hepatitis B virus infection
⇑
European Association for the Study of the Liver
Introduction been increasing over the last decade as a result of aging of the
HBV-infected population and predominance of specific HBV
Our understanding of the natural history of hepatitis B virus genotypes and represents the majority of cases in many areas,
(HBV) infection and the potential for therapy of the resultant dis- including Europe [4,9,10]. Morbidity and mortality in CHB are
ease is continuously improving. New data have e available linked to persistence of viral replication and evolution to cirrhosis
since the previous EASL Clinical Practice Guidelines (CPGs) pre- and/or hepatocellular carcinoma (HCC). Longitudinal studies of
pared in 2008 and published in early 2009 [1]. The objective of untreated patients with CHB indicate that, after diagnosis, the
this manuscript is to update the mendations for the opti- 5-year cumulative incidence of developing cirrhosis ranges
mal management of chronic HBV infection. The CPGs do not fully from 8% to 20%. The 5-year cumulative incidence of hepatic
address prevention including ination. In addition, despite the pensation is approximately 20% for untreated patients
increasing knowledge, areas of uncertainty still exist and there- pensated cirrhosis [2–4,11–13]. Untreated patients with
fore clinicians, patients, and public health authorities must con- pensated cirrhosis have a poor prognosis with a 14–35%
tinue to make choices on the basis of the evolving evidence. probability of survival at 5 years [2–4,12]. The worldwide inci-
dence of HCC has increased, mostly due to persistent HBV and/
or HCV infections; presently it constitutes the fifth mon
Context cancer, representing around 5% of all cancers. The annual inci-
dence of HBV-related HCC in patients with CHB is high, ranging
Epidemiology and public health burden from 2% to 5% wh